Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 2/20 | 0.48 |
| ▸ | KIT | P10721 | 2/20 | 0.48 |
| ▸ | FLT1 | P17948 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | ABL2 | P42684 | 2/20 | 0.48 |
| ▸ | FLT4 | P35916 | 1/20 | 0.48 |
| ▸ | LEF1 | Q9UJU2 | 1/20 | 0.41 |
| ▸ | F11 | P03951 | 2/20 | 0.35 |
| ▸ | PYGL | P06737 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 5/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | NR1I3 | Q14994 | 3/20 | 0.34 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.34 |
| ▸ | SCN4A | P35499 | 1/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6520370 | 1.00 | ADH1A (0.48) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL29363107 | 0.94 | ADH1A (0.48) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL13311107 | 0.93 | LEF1 (0.41) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL16802302 | 0.92 | ADH1A (0.43) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL29357321 | 0.89 | ADH1A (0.44) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL6517373 | 0.89 | ADH1A (0.52) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL6517367 | 0.89 | ADH1A (0.52) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL13311220 | 0.88 | LEF1 (0.37) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL17805677 | 0.88 | LEF1 (0.44) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL6512534 | 0.88 | KDR (0.52) | ADH1AKITFLT1KDRABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461117-B2 | Chemical linkers and cleavable substrates and conjugates thereof | MEDAREX, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461117-B2 | Chemical linkers and cleavable substrates and conjugates thereof | MEDAREX, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20050026987-A1 | CBI analogues of the duocarmycins and CC-1065 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026987-A1 | CBI analogues of the duocarmycins and CC-1065 | CCNI, SP1, DCK | ADH1A 4729/4885KIT 1086/4885FLT1 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.